














FIG. 2









FIG. 5A.



மேல்





FIG. 5C



50




FIG. 5E




FIG. 6A

Cohort 6a ADA Response Values and Titer




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8B




FIG. 8A




FIG. 8D

FIG. 8C






FIG. 8E



Parameter	Cohort 7	Cohort A	Cohort B	Cohort C	Cohort D
Cmax (ng/mL)	5.7	8.8	11.8	14.7	24.5
Tmax (days)	49.3	49.2	49.2	49.2	49.2
Cmin* (ng/mL)	0.80	1.22	1.62	2.04	3.37
AUC** (ng*day/mL)	92.7	179.4	239.2	308.5	466.3


FIG. 9A

*Cmin: trough concentrations prior to Cmax
**Calculated for D1-D56 (through Cycle 2)

Cohort	Cmax:Cmin* at Cmax	ACU:Cmax	Highest Cmax:Cmin in Cycle 1	
			Dose	Dose Cmax:Cmin*
Cohort 7	7.07	16.3	C1D22	9.54
Cohort A	7.26	20.4	C1D22	6.76
Cohort B	7.26	20.3	C1D22	6.75
Cohort C	7.23	21.0	C1D22	6.42
Cohort D	7.29	19.0	C1D22	7.18

FIG. 9B

*Cmin: C1 Cmin prior to C1 Cmax






FIG. 11

FIG. 12




FIG. 13A

Patient Characteristics										Treatment and Outcomes									
Patient ID	Cohort	TR1130 Dose (µg/kg)	TR1130 Dose (flat dose, µg/week)	Age/Sex/Race	WHO Classification	Previous Therapies (Number, Venetoclax and/or Decitabine)	Percent Myeloblasts	Karyotype/Mutations	CRS (Grade)	Grade 3-5 AE	SAE	Neurotoxicity	DLT	Best Overall Response	Time to Progression (days)	Time to Death or Hospice	Survival Status at last FU		
UPN01	6B	0.1	12	76/M/ C	AML with MDS-rf	1; Venetoclax +Decitabine	29	7,del(5q)/TP53 NF1	No	No	No	Insomnia (G1), CID11, 18d	No	CR	288	>352	A		
UPN02	6B	0.2	12	58/F/C	AML with MDS-rf	2; Venetoclax + Decitabine	6	7,del(5q),del(17p)/TP53	No	No	No	None	No	PD	38	122	D		
UPN03	6A	0.2	18	65/F/C	AML with recurrent genetic abn.	4; Venetoclax + AZA	40	inv(16)/ND	No	No	No	No	No	SD/RES	NA	75	D		
UPN04	6B	0.3	12	40/F/C	AML with MDS-rf-gene mutations	8; Venetoclax +Decitabine	29	t(1;15)(5;10) 11q23/FLT3-ITD	No	No	No	No	No	PD	49	97	D		
UPN05	6A	0.4	18	73/F/C	AML- NOS/MO	2; Venetoclax + AZA	15	46, XX, del(20)(q11.2q13.1)(ND)	C6D17 (G1,2d)	Sepsis(3), Diarrhea(3), Vomiting(3) (C6D15, 5d)	Sepsis(3), Diarrhea(3), Vomiting(3) (C6D15, 5d)	Dizziness (1), Lethargy(1), C8D15-22	No	SD	288	>395	A		
UPN06	7	0.4	24	78/F/C	AML with MDS-rf	4; AZA	78	46,XX/None	C5D1 (G2,2d)	Confusion (G3,C1D1,1d) No	C5D1 (G2 CRS,2d)	Confusion (G3,C1D1,1d)	SD+ PBBC-C+ >50% BLR-BM	SD	211	282	D		
UPN07	10	0.7	60	47/M/ B	AML with mutated RUNX1	3; Decitabine	4	t(2;15)/ NF1,RUNX1, GATA2,IKZF1	No	No	No	No	No	SD	>106	>110	A		
UPN08	10	0.7	60	82/M/ C	AML with gene mutations	2; Venetoclax + AZA	50	-Y/FLT3-ITD	No	No	No	No	No	SD/RES	>117	>124	A		

FIG. 13B

Patient ID ^s	Cohort	APVO 436 Dose (mcg/kg)	APVO 436 Dose (mcg/weeks)	Age/Sex/Race	WHO Classification	IPSS Prognosis Score (Risk Group)	Karyotype	Previous Therapies (Number: HMA or Venetoclax + HMA)	CRS(Grade)	Grade 3-5 AE	SAE	Neurotoxicity	DLT	Percent Myeloblasts- PRE	Percent Myeloblasts- POST	Best Overall Response	Time to Progression (Days)	Time to Death or Hospice (Days)	Survival Status at last FU
UPN09	4	0.1	9	77/F/C	MDS-EB-1	1.5(IM-2)	Intermediate	1: Decitabine	No	>3*	No	No	No	8	4(C10D22)	SD	321	330	D
UPN10	6A	0.2	18	80/M/C	MDS-EB-1	1.0(IM-1)	Good	1: AZA	No	No	No	No	No	7.5	2.4(C2D1)	Marrow CR - SD	138	138	D
UPN11	7	0.3	24	75/M/C	MDS-EB-2	2.5(High)	Intermediate	3: Decitabine	No	No	No	No	No	11.3	0(C2D1)	Marrow CR - SD	104	138	D
UPN12	9	0.4	48	75/M/C	MDS-EB-1	0.5(IM-1)	Good	1: AZA	No	No	No	No	No	8.2	2(C2D1)	Marrow CR - SD	147	>167	A
UPN13	8	0.5	36	69/M/A	MDS-EB-1	2.0(IM-2)	Poor	2: Venetoclax AZA	C2D1 (G1)	No	No	No	No	5	5(C2D1)	SD	211	>232	A
UPN14	10	0.8	60	74/F/C	MDS-EB-1	1.5(IM-2)	Intermediate	1: AZA	No	No	No	No	No	6	6(C3D1)	SD	>78	>78	A

FIG. 14

UPN	Clinical Response	IFN- γ (pg/mL)		IL-5 (pg/mL)		IL-10 (pg/mL)	
		Predose	Post C2D1	Predose	Post C2D1	Predose	Post C2D1
UPN01(AML)	PR—CR	16.7 (0.4)	34.7** (1.3)-E 10.0 (1.9)-L	0.4 (0.08)	0.6 (0.1)-E 0.2 (0.05)L	0.2 (0.04)	0.3 (0.05)-E 9.2* (0.3)-L
UPN05(AML)	SD	5.0 (0.7)	9.0 (2.6)-E 9.7** (1.3)-L	-	-	0.4 (0.08)	0.4 (0.01)-E 3.3* = 0.2-L
UPN06(AML)	PBBC-C	2.9 (-)	3.5 (0.5)	5.4 (0.2)	10.4*** (4.3)-E 7.5 (0.2)-L	0.7 (0.02)	1.7 (0.07)-E 12.1* (0.7)-L
UPN09(MDS)	SD	350.2 (4.1)	130.6 (12.2)	0.1	0.2	7.1 (0.2)	1.7 $\pm$ 0.2
UPN10(MDS)	Marrow CR	3.4 (1.3)	3.1 (-)	1.4 (0.03)	1.1 (0.07) 0.4 (0.05)	0.4 (0.05)	0.3 (0.01)-E 9.8* (0.3)-L
UPN13(MDS)	SD	2.6 (-)	-	0.4 (0.05)	0.6 (0.03)	0.8 (0.03)	0.7 (0.03)

UPN	Putative CD123 ⁺ LSC CD123 ⁺ CD34 ⁺ CD38 ⁻ Number (% of CD45+)/% Depletion	Putative CD33 ⁺ LSC CD33 ⁺ CD34 ⁺ CD38 ⁻ Number (% of CD45+)/ % Depletion	CD45 ⁺
UPN01/AML			
Baseline/C1D1	155 (0.16%)	156 (0.17%)	94,415
C2D15	74 / 52.3%	73 / 53.2%	86,266
C4D1	717 54.2%	72 / 53.8%	89848
C6D1	37 (0.04%) / 76.1%	36 (0.04%) / 76.9%	84,337
UPN03/AML			
Baseline/C1D1	2757 (2.8%)	2732 (2.8%)	97928
EOT/C1D30	1163 (1.2%) / 57.8%	1153 (1.2%) / 57.8%	93827
UPN05/AML			
Baseline/C1D1	13782 (15.4%)	13147 (14.7%)	99598
C2D15	21115 / 0%	17185 / 0%	94131
C4D1	22787 / 0%	18565 / 0%	96053
C6D1	23653 (=24.3% of CD45+) / 0%	15001 (=15.4% of CD45+) / 0%	97346
UPN06/AML			
Baseline/C1D1	1569 (1.7%)	1552 (1.7%)	92694
C2D15	24 / 98.5%	23 / 98.5%	92219
C4D1	12 (0.01%) / 99.2%	12 (0.01%) / 99.2%	92694
C6D1	33 (=0.01% of CD45+) / 97.9%	32 (=0.01% of CD45+) / 97.9%	93863
UPN09/MDS			
Baseline/C1D1	1441 (1.52%)	907 (0.96%)	94715
C2D1	1489 / 0%	1191 / 0%	94300
C4D1	947 / 34.3%	575 / 36.6%	95129
C6D1	1419 / 4.7%	1421 / 0%	94893
UPN10/MDS			
Baseline/C1D1	833 (0.9%)	836 (0.9%)	972155
C2D15	833 / 0%	775 / 7.3%	101335
C4D1	477 (0.48%) / 42.7%	457 / 45.8%	99979
EOT/C5D20	2567 (2.5%) / 3.1-fold expansion)	2296 (2.3%) / 2.7-fold expansion	100884

UPN03 had 40% bone marrow blasts at screening and also 40% at C1D22. EOT was on C1D30.

UPN10 has 7.5% bone marrow blasts at screening and 20% bone marrow blasts on C5D1. EOT was on C5D20.

FIG. 15